<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: To simulate human <z:hpo ids='HP_0001297'>stroke</z:hpo>, we developed a model of focal cerebral embolic <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the unanesthetized rat </plain></SENT>
<SENT sid="1" pm="."><plain>Using this model, we tested the hypothesis that intra-arterial administration of TNK-tPA, a fibrin specific second generation thrombolytic agent, is effective in reducing ischemic volume without increasing intra-<z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Under anesthesia, a catheter was inserted to the origin of the <z:chebi fb="70" ids="34342">MCA</z:chebi> of male Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-five minutes after recovery from anesthesia, the <z:chebi fb="70" ids="34342">MCA</z:chebi> was occluded in the awake rat by a single fibrin rich clot placed via the catheter </plain></SENT>
<SENT sid="4" pm="."><plain>TNK-tPA (1.5 mg/kg) was administered intraarterially via the catheter at either 2 h or 4 h after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> rats were sacrificed at 48 h after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Neurological deficits, gross <z:mp ids='MP_0001914'>hemorrhage</z:mp> and ischemic lesion volume were measured </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: A clot was detected at the origin of the <z:chebi fb="70" ids="34342">MCA</z:chebi> 4 h after <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion in the awake rats (n=4) </plain></SENT>
<SENT sid="8" pm="."><plain>Rats (n=12) subjected to <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion showed immediate neurological deficits which persisted for 48 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Ischemic rats had a lesion volume of 38.2+/-3.8% and 25% of rats exhibited gross <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Ischemic rats (n=10) treated with TNK-tPA at 2 h showed a significant (P&lt;0.05) reduction of neurological deficits, body <z:hpo ids='HP_0001824'>weight loss</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (22.8+/-2.1%) without an increase in gross <z:mp ids='MP_0001914'>hemorrhage</z:mp> (10%) compared with the non treated ischemic rats (25%) </plain></SENT>
<SENT sid="11" pm="."><plain>Although treatment with TNK-tPA of ischemic rats (n=12) at 4 h did not significantly (P=0.06) reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (28.6+/-3.0%), it also did not increase gross <z:mp ids='MP_0001914'>hemorrhage</z:mp> (25%) compared with the control group (25%) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: This study demonstrates that intraarterial administration of TNK-tPA at 2 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in the unanesthesthetized rat is effective in reducing neurological deficits and ischemic lesion volume without increasing hemorrhagic transformation and that administration of TNK-tPA at 4 h of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> does not increase the incidence of hemorrhagic transformation </plain></SENT>
</text></document>